| Revenue growth | 19% YoY net revenue growth to ₹1,129 Cr. |
|---|---|
| Margins | Improving, EBITDA margin reached 15% vs 14.3% last year. |
| Demand visibility | Strong Spirits demand; mixed visibility in Chemicals due to exports. |
| Management confidence | Extremely high, using aspirational multi-year EBITDA targets. |
Growth
Revenue grew 19% YoY to ₹1,129 Cr, supported by a 65% surge in Bio-Pharma revenues.
Outlook
Aspirations to deliver ₹500 Cr EBITDA in Spirits and ₹2,500 Cr revenue in Chemicals over 4-5 years.
Risks
High volatility in freight rates (up 5-20x) and raw material costs like Ethylene Oxide pose margin risks.
Last quarter's promises, checked
Delivered
- Guided 20% ethanol blending → reached 20% (= BEAT)
- Guided debt reduction → prepaid ₹804 Cr debt (= BEAT)
- Guided IMFL premiumization → 25% UP top-line growth (= BEAT)
Partly delivered
- Guided Chemicals growth → Net revenue down 10.4% despite EBIT rise (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: INDIAGLYCO. Summary written with AI assistance from the document.
India Glycols Ltd: key numbers
- Share price
- ₹382.70
- Market cap
- ₹2,565 Cr
- Revenue (annual)
- ₹4,211 Cr
- Net profit (annual)
- ₹292.8 Cr
- P/E (TTM)
- 8.1×Sector 36.8×
- Promoter holding
- 59.63%+0.00% QoQ
- FII holding
- 2.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from India Glycols Ltd
All →India Glycols Board Meeting Outcome
India Glycols Limited announced that its subsidiary, IGL Spirits Limited, approved share allotment under a Scheme of Arrangement and appointed new key managerial personnel.
India Glycols Management Change
India Glycols Ltd announced that four senior management personnel ceased their roles following the effective date of a previously disclosed Scheme of Arrangement.
India Glycols Merger & Restructuring
India Glycols Limited has completed its demerger into three separate entities effective September 1, 2026. The scheme, sanctioned by the NCLT, is now operational.
India Glycols Management Change
India Glycols' subsidiary, Ennature Bio Pharma, announced the appointment of new Directors and a Managing Director. These appointments are part of ongoing corporate updates.
India Glycols Merger & Restructuring
India Glycols Ltd received the certified NCLT order approving the Scheme of Arrangement, which involves the demerger of its Biopharma, Spirits, and Biofuel undertakings.
India Glycols Annual General Meeting
India Glycols held its 42nd Annual General Meeting on August 19, 2026. Shareholders approved all resolutions, including the final dividend payout.